X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
Australia
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
https://www.astrazeneca.com/media-centre/press-releases/2024/voydeya-approved-in-the-eu-as-add-on-treatment-to-ravulizumab-or-eculizumab-for-adults-with-rare-disease-pnh-who-have-residual-haemolytic-anaemia.html#:~:text=Voydeya%20(danicopan)%20has%20been%20approved,who%20have%20residual%20haemolytic%20anaemia.
https://www.astrazeneca.com/media-centre/press-releases/2024/voydeya-recommended-for-eu-approval.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125166
https://www.astrazeneca.com/media-centre/press-releases/2023/soliris-approved-japan-paediatric-patients-generalised-myasthenia-gravis-gmg.html
https://www.astrazeneca.com/media-centre/press-releases/2023/soliris-approved-in-the-eu-for-children-and-adolescents-with-refractory-generalised-myasthenia-gravis-gmg.html#:~:text=Soliris%20(eculizumab)%20has%20been%20approved,antibody%2Dpositive%20(Ab%2B).
https://www.ema.europa.eu/en/documents/overview/bekemv-epar-medicine-overview_en.pdf
https://www.astrazeneca.com/media-centre/press-releases/2023/soliris-recommended-for-approval-in-the-eu-by-chmp-for-children-and-adolescents.html#:~:text=Soliris%20(eculizumab)%20has%20been%20recommended,antibody%2Dpositive%20(Ab%2B).
https://www.pharmatimes.com/news/astrazenecas_soliris_given_eu_chmp_recommendation_for_marketing_authorisation_1493867
https://www.astrazeneca.com/media-centre/press-releases/2023/soliris-approved-in-china-for-the-treatment-of-adults-with-refractory-generalised-myasthenia-gravis.html
https://www.ema.europa.eu/en/documents/overview/epysqli-epar-medicine-overview_en.pdf
https://www.europeanpharmaceuticalreview.com/news/183025/european-commission-approves-haematology-biosimilar/
https://www.ema.europa.eu/en/documents/overview/bekemv-epar-medicine-overview_en.pdf
https://www.globenewswire.com/news-release/2023/03/31/2638602/0/en/Samsung-Bioepis-Receives-Positive-CHMP-Opinion-for-Eculizumab-Biosimilar-EPYSQLI.html
https://www.pharmaceutical-technology.com/news/health-canada-sobi-pnh-therapy/
https://www.biospace.com/article/releases/danicopan-alxn2040-add-on-to-ultomiris-ravulizumab-cwvz-or-soliris-eculizumab-met-primary-endpoint-in-alpha-phase-iii-trial-for-patients-with-paroxysmal-nocturnal-hemoglobinuria/?s=69
https://www.globenewswire.com/news-release/2022/06/10/2460245/0/en/Samsung-Bioepis-Presents-New-Phase-3-Study-of-SB12-Eculizumab-A-Proposed-Biosimilar-to-Soliris-at-the-European-Hematology-Association-EHA-Congress-2022.html
https://www.fiercepharma.com/pharma/astrazenecas-ultomiris-continues-its-rapid-ascent-fda-nod-generalized-myasthenia-gravis
https://www.fiercebiotech.com/biotech/alexion-arvinas-biotech-sign-space-future-10-story-biotech-tower
https://www.fiercepharma.com/marketing/argenx-vyvgart-a-collision-course-astrazeneca-s-soliris-as-both-battle-for-market-share
https://www.fiercepharma.com/pharma/astrazeneca-s-soliris-needs-a-97-to-98-discount-myasthenia-gravis-icer-says
https://endpts.com/on-the-back-of-phiii-success-astrazeneca-lays-out-the-carpet-for-rare-disease-drug-alexion-paid-855m-for/
https://www.reuters.com/article/us-astrazeneca-rare-diseases/eu-regulator-backs-astrazeneca-drug-for-rare-blood-disorder-in-children-idUSKBN2EW0IE
https://www.fiercepharma.com/pharma/astrazeneca-s-newly-acquired-soliris-needs-substantial-discount-myasthenia-gravis-cost
https://endpts.com/bristol-myers-squibb-takes-another-late-stage-loss-for-opdivo-yervoy-combo-in-head-and-neck-cancer/
https://endpts.com/days-after-fda-clears-c3-drug-apellis-spotlights-ex-us-phiii-win-among-patients-who-havent-taken-soliris/
https://www.globenewswire.com/news-release/2021/05/12/2228361/0/en/Apellis-to-Present-Long-Term-Pegcetacoplan-Data-in-PNH-at-the-European-Hematology-Association-Virtual-Congress.html
http://www.pharmatimes.com/news/nice_recommends_alexions_pnh_treatment_ultomiris_1367123
http://www.pharmafile.com/news/576183/first-approved-c5-complement-inhibitor-recommended-nice-nhs-use
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125166
https://endpts.com/apellis-soliris-rival-gets-a-date-at-the-fda-for-a-rare-blood-disorder-with-potentially-400m-worth-of-implications/
https://endpts.com/novartis-succeeds-where-alexion-failed-coming-up-with-a-win-for-a-prized-asset-in-a-rare-kidney-disorder/
https://www.fiercebiotech.com/biotech/novartis-targets-alexion-s-fiefdom-after-showing-pnh-patients-can-safely-switch-from
https://www.bigmoleculewatch.com/2020/06/11/alexion-and-amgen-settle-iprs-over-soliris-eculizumab/
https://www.dksh.com/global-en/home/media/news?id=tag:xml.newsbox.ch,2020-06-11:1101.2493.digest
https://investors.apellis.com/news-releases/news-release-details/new-pivotal-data-demonstrate-superiority-apellis-pegcetacoplan
https://www.centerforbiosimilars.com/news/alexion-settles-with-amgen-over-eculizumab-patents
https://endpts.com/in-a-post-soliris-world-atlas-backed-q32-bio-outlines-46m-next-gen-complement-play/
https://endpts.com/apellis-says-its-ready-to-file-for-an-ok-on-their-soliris-rival-after-regulators-clear-a-roadblock/
https://www.fiercebiotech.com/biotech/genentech-posts-long-term-data-near-approval-soliris-rival
http://www.pmlive.com/pharma_news/alexion_will_test_rare_disease_drug_ultomiris_in_severe_covid-19_1338682
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125166
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125166
https://www.fiercepharma.com/pharma/alexion-to-its-detractors-take-a-look-at-our-soliris-switching-and-robust-pipeline
Market Place
Share 
